Laurus Labs Limited (LAURUSLABS.NS)
INR 571.5
(0.8%)
INR 571.5
(0.8%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 15.44 Billion INR | -51.51% |
| 2022 | 32.66 Billion INR | 23.71% |
| 2021 | 26.4 Billion INR | 4.53% |
| 2020 | 25.25 Billion INR | 92.14% |
| 2019 | 13.14 Billion INR | 34.39% |
| 2018 | 9.78 Billion INR | 7.5% |
| 2017 | 9.09 Billion INR | 7.8% |
| 2016 | 8.44 Billion INR | 42.95% |
| 2015 | 5.9 Billion INR | 62.79% |
| 2014 | 3.62 Billion INR | 2.85% |
| 2013 | 3.52 Billion INR | 39.67% |
| 2012 | 2.52 Billion INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 3.78 Billion INR | -16.79% |
| 2024 Q2 | 6.75 Billion INR | 78.67% |
| 2023 Q4 | 4.54 Billion INR | -30.05% |
| 2023 FY | 15.83 Billion INR | -51.51% |
| 2023 Q1 | 5.97 Billion INR | -12.89% |
| 2023 Q2 | 6.43 Billion INR | 7.61% |
| 2023 Q3 | 6.49 Billion INR | 0.95% |
| 2022 Q4 | 6.86 Billion INR | -16.85% |
| 2022 Q1 | 8.85 Billion INR | 38.44% |
| 2022 Q2 | 8.68 Billion INR | -1.98% |
| 2022 FY | 32.66 Billion INR | 23.71% |
| 2022 Q3 | 8.25 Billion INR | -4.96% |
| 2021 Q3 | 6.04 Billion INR | -9.85% |
| 2021 Q2 | 6.7 Billion INR | -7.43% |
| 2021 FY | 26.4 Billion INR | 4.53% |
| 2021 Q1 | 7.24 Billion INR | 10.69% |
| 2021 Q4 | 6.39 Billion INR | 5.83% |
| 2020 Q3 | 7.05 Billion INR | 10.63% |
| 2020 FY | 25.25 Billion INR | 92.14% |
| 2020 Q1 | 5.28 Billion INR | 66.59% |
| 2020 Q4 | 6.54 Billion INR | -7.18% |
| 2020 Q2 | 6.37 Billion INR | 20.69% |
| 2019 Q1 | 2.76 Billion INR | 28.29% |
| 2019 FY | 13.14 Billion INR | 34.39% |
| 2019 Q4 | 3.17 Billion INR | -14.07% |
| 2019 Q3 | 3.69 Billion INR | 4.71% |
| 2019 Q2 | 3.52 Billion INR | 27.69% |
| 2018 Q1 | 2.43 Billion INR | -9.45% |
| 2018 Q4 | 2.15 Billion INR | -12.37% |
| 2018 FY | 9.78 Billion INR | 7.5% |
| 2018 Q3 | 2.45 Billion INR | -10.28% |
| 2018 Q2 | 2.73 Billion INR | 12.21% |
| 2017 Q1 | 2.32 Billion INR | -7.72% |
| 2017 FY | 9.09 Billion INR | 7.8% |
| 2017 Q2 | 2.57 Billion INR | 10.56% |
| 2017 Q3 | 2.33 Billion INR | -9.36% |
| 2017 Q4 | 2.69 Billion INR | 15.5% |
| 2016 Q4 | 2.52 Billion INR | 12.16% |
| 2016 Q1 | 1.97 Billion INR | 0.0% |
| 2016 FY | 8.44 Billion INR | 42.95% |
| 2016 Q3 | 2.24 Billion INR | -3.84% |
| 2016 Q2 | 2.33 Billion INR | 18.63% |
| 2015 FY | 5.9 Billion INR | 62.79% |
| 2014 FY | 3.62 Billion INR | 2.85% |
| 2013 FY | 3.52 Billion INR | 39.67% |
| 2012 FY | 2.52 Billion INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Sigachi Industries Limited | 2 Billion INR | -671.554% |
| Ind-Swift Limited | 2.17 Billion INR | -611.092% |
| Bajaj HealthCare Limited | 1.47 Billion INR | -949.642% |
| Sakar Healthcare Limited | 699.58 Million INR | -2108.266% |
| Aurobindo Pharma Limited | 109.54 Billion INR | 85.897% |
| Innova Captab Limited | 3.46 Billion INR | -345.922% |
| Divi's Laboratories Limited | 32.44 Billion INR | 52.378% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | -148.264% |
| Morepen Laboratories Limited | 6.16 Billion INR | -150.738% |
| Mankind Pharma Limited | 42.19 Billion INR | 63.389% |
| Sequent Scientific Limited | 2.97 Billion INR | -418.634% |
| Wanbury Limited | 1.73 Billion INR | -792.657% |
| Nectar Lifesciences Limited | 4.82 Billion INR | -220.294% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | -24.256% |
| Alembic Limited | 1 Billion INR | -1444.705% |
| Hikal Limited | 5.95 Billion INR | -159.293% |
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 42.314% |
| Neuland Laboratories Limited | 8.24 Billion INR | -87.306% |
| J. B. Chemicals & Pharmaceuticals Limited | 15.25 Billion INR | -1.244% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 77.721% |
| IOL Chemicals and Pharmaceuticals Limited | 4.71 Billion INR | -227.365% |
| Themis Medicare Limited | 2.42 Billion INR | -538.374% |
| RPG Life Sciences Limited | 2.48 Billion INR | -522.179% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 87.662% |
| Lupin Limited | 125.09 Billion INR | 87.65% |
| Amrutanjan Health Care Limited | 2.09 Billion INR | -637.747% |
| Wockhardt Limited | 7.72 Billion INR | -100.113% |
| Vaishali Pharma Limited | 90.32 Million INR | -17003.838% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | -164.925% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -2267.29% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 21.353% |
| FDC Limited | 6.58 Billion INR | -134.561% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 90.557% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -2389.81% |
| Eris Lifesciences Limited | 10.42 Billion INR | -48.164% |
| Venus Remedies Limited | 2.18 Billion INR | -607.817% |
| ZIM Laboratories Limited | 1.26 Billion INR | -1118.531% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | -318.048% |
| Par Drugs and Chemicals Limited | 529.13 Million INR | -2819.609% |
| Caplin Point Laboratories Limited | 9.2 Billion INR | -67.802% |
| Shilpa Medicare Limited | 3.56 Billion INR | -333.721% |
| Albert David Limited | 1.4 Billion INR | -997.141% |
| Ajanta Pharma Limited | 21.06 Billion INR | 26.658% |
| Hester Biosciences Limited | 1.27 Billion INR | -1112.947% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | -274.671% |
| Solara Active Pharma Sciences Limited | -1.65 Billion INR | 1032.949% |
| Gufic Biosciences Limited | 4.07 Billion INR | -279.227% |
| Windlas Biotech Limited | 1.33 Billion INR | -1053.921% |
| Procter & Gamble Health Limited | 5.78 Billion INR | -167.214% |
| Aarey Drugs & Pharmaceuticals Limited | 113.02 Million INR | -13567.908% |
| Mangalam Drugs & Organics Limited | 691.19 Million INR | -2135.078% |
| Granules India Limited | 16.79 Billion INR | 8.04% |
| Aarti Drugs Limited | 8.31 Billion INR | -85.766% |
| Bal Pharma Limited | 770.19 Million INR | -1905.817% |
| Alkem Laboratories Limited | 52.29 Billion INR | 70.46% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 94.023% |
| Lincoln Pharmaceuticals Limited | 1.88 Billion INR | -718.749% |
| Medicamen Biotech Limited | 495.49 Million INR | -3017.832% |
| Unichem Laboratories Limited | 4.86 Billion INR | -217.552% |
| Bafna Pharmaceuticals Limited | 452.15 Million INR | -3316.697% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.54 Million INR | -123046.273% |
| Valiant Laboratories Limited | 138.02 Million INR | -11092.358% |
| Orchid Pharma Limited | 2.32 Billion INR | -565.805% |
| Medico Remedies Limited | 262.14 Million INR | -5793.211% |
| Ind-Swift Laboratories Limited | 4.13 Billion INR | -273.769% |
| Ipca Laboratories Limited | 48.58 Billion INR | 68.202% |
| Brooks Laboratories Limited | 65.62 Million INR | -23442.67% |
| Syncom Formulations (India) Limited | 559.5 Million INR | -2661.147% |
| Piramal Enterprises Limited | 8.04 Billion INR | -92.069% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 66.96% |
| NATCO Pharma Limited | 25.73 Billion INR | 39.972% |
| Suven Life Sciences Limited | -200.79 Million INR | 7793.691% |
| Krebs Biochemicals & Industries Limited | -108.74 Million INR | 14306.093% |
| Strides Pharma Science Limited | 14.38 Billion INR | -7.371% |
| Indoco Remedies Limited | 8.04 Billion INR | -92.076% |
| Alpa Laboratories Limited | 188.89 Million INR | -8078.459% |
| Lasa Supergenerics Limited | 121.02 Million INR | -12664.356% |
| Sun Pharma Advanced Research Company Limited | 391.06 Million INR | -3850.407% |